BioCentury
ARTICLE | Company News

Weill Cornell Medical College, Cellectis deal

July 27, 2015 7:00 AM UTC

Weill Cornell and Cellectis partnered to develop Cellectis’ UCART123 -- chimeric antigen receptor (CAR)-modified allogeneic T cells -- for patients with acute myelogenous leukemia (AML). During the p...